Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

Journal of Clinical Oncology

Volumn 26, Issue 13, 2008, Pages 2171-2177

  Rajkumar, S Vincent ^a   Rosiñol, Laura ^a   Hussein, Mohamad ^a   Catalano, John ^a   Jedrzejczak, Wieslaw ^a   Lucy, Lela ^a   Olesnyckyj, Marta ^a   Yu, Zhinuan ^a   Knight, Robert ^a   Zeldis, Jerome B ^a   Bladé, Joan ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; PLACEBO; THALIDOMIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER GROWTH; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; INFECTION; INSOMNIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NEUROPATHY; NEUTROPENIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYNCOPE; TREATMENT RESPONSE; TREMOR; WEIGHT GAIN; AUSTRALIA; DRUG ADMINISTRATION; EUROPE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; TIME; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALIA; DEXAMETHASONE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 43749117945     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.1853     Document Type: Article

References (36)

1. Sirohi B, Powles R: Multiple myeloma. Lancet 363:875-887, 2004
2. Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med 351:1860-1873, 2004
3. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91-97, 1996
4. Child JA, Morgan GJ, Davies FE, et al: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875-1883, 2003
5. Rajkumar SV, Hayman S, Gertz MA, et al: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319-4323, 2002
6. Weber D, Rankin K, Gavino M, et al: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16-19, 2003
7. Cavo M, Zamagni E, Tosi P, et al: First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologia (Budap) 89:826-831, 2004
8. Cavo M, Zamagni E, Tosi P, et al: Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106:35-39, 2005
9. Macro M, Divine M, Uzunhan Y, et al: Dexamethasone+thalidomide (dex/thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): A randomized trial. Blood 108:22a, 2006 (abstr 57)
10. Jimenez-Zepeda V, Dominguez-Martinez V: Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma? Eur J Haematol 77:239-244, 2006
11. Rajkumar SV, Blood E, Vesole D, et al: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431-436, 2006
12. Bladé J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT - European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123, 1998
13. Durie BG, Harousseau J, Miguel J, et al: International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473, 2006
14. Kaplan EL, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 53:457-481, 1958
15. Singhal S, Mehta J, Deskian R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999
16. Barlogie B, Desikan R, Eddlemon P, et al: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492-494, 2001
17. Kumar S, Gertz MA, Dispenzieri A, et al: Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 78:34-39, 2003
18. Richardson P, Schlossman R, Jagannath S, et al: Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: Results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 79:875-882, 2004
19. Weber DM, Rankin K, Gavino M, et al:Thalidomide with dexamethasone for resistant multiple myeloma. Blood 96:167a, 2000 (abstr 719)
20. Anagnostopoulos A, Weber D, Rankin K, et al: Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121:768-771, 2003
21. Palumbo A: Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86:399-403, 2001
22. Attal M, Harousseau J-L, Facon T, et al: Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495-2502, 2003
23. Harousseau J-L, Attal M, Moreau P, et al: The prognostic impact of complete remission (CR) plus very good partial remission (VGPR) in a double-transplantation program for newly diagnosed multiple myeloma (MM): Combined results of the IFM 99 trials. Blood 108:A3077, 2006
24. Facon T, Mary J-Y, Pegourie B, et al: Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 107:1292-1298, 2006
25. Osman K, Comenzo RL, Rajkumar SV: Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 344:1951-1952, 2001
26. Palumbo A, Bringhen S, Caravita T, et al: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomized controlled trial. Lancet 367:825-831, 2006
27. Knight R, DeLap RJ, Zeldis JB: Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354:2079-2080, 2006
28. Facon T, Mary JY, Hulin C, et al: Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 370:1209-1218, 2007
29. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
30. Richardson PG, Sonneveld P, Schuster MW, et al: Assessment of proteasome inhibition for extending remissions, I: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005
31. Jagannath S, Durie BG, Wolf J, et al: Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129:776-783, 2005
32. Harousseau J, Attal M, Leleu X, et al: Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study. Haematologica 91:1498-1505, 2006
33. Richardson PG, Schlossman RL, Weller E, et al: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063-3067, 2002
34. Rajkumar SV, Hayman SR, Lacy MQ, et al: Combination therapy with lenalidomide plus dexamethasone (Rev/dex) for newly diagnosed myeloma. Blood 106:4050-4053, 2005
35. Bartlett JB, Tozer A, Stirling D, et al: Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer 93:613-619, 2005
36. Bruno B, Rotta M, Patriarca F, et al: A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356:1110-1120, 2007